PURPOSE: Chemotherapy emetogenicity is the most important known determinant of chemotherapy-induced @entity391 ( @entity4609 ) in @entity1 . However, direct evidence regarding the emetogenic potential of chemotherapeutic agents in @entity1 is limited. This study describes the prevalence of complete control of acute and delayed phase chemotherapy-induced @entity1209 (CINV) in @entity1 receiving @entity1499 . The prevalence of anticipatory CINV is described, and risk factors for CINV are explored. METHODS: English-speaking @entity1 (4 to 18  years) receiving intermediate-dose (ID- @entity6822 : >1 to <12  g/m(2)/dose) or high-dose @entity1499 ( @entity2033 - @entity6822 : >= 12  g/m(2)/dose) participated in this prospective study. @entity2749 , @entity390 severity, and antiemetic administration were documented for 24  h from the start of the @entity1499 infusion (acute phase) and for up to a further 168  h (delayed phase). CINV prophylaxis was provided at the discretion of the treating physician. Anticipatory CINV was assessed in the 24  h preceding chemotherapy. Complete CINV control was defined as no emetic episodes and no @entity390 . RESULTS: Thirty @entity1 (mean age, 11.8      4  years; ID- @entity6822 , 20; @entity2033 - @entity6822 , 10) completed the study. CINV prophylaxis included the following: @entity3974 / @entity10442 plus @entity619 or @entity36584 . Few @entity1 experienced complete CINV control (ID- @entity6822 : acute phase 20  %, delayed phase 5  %; @entity2033 - @entity6822 : acute phase 0  %, delayed phase 30  %). Complete emesis control was higher (ID- @entity6822 : acute phase 70  %, delayed phase 50  %; @entity2033 - @entity6822 : acute phase 70  %, delayed phase 60  %). Anticipatory CINV was reported by 6/28 @entity1 (21  %). @entity1 age, sex, and history of motion sickness were not significant predictors of CINV. CONCLUSIONS: The poor complete CINV control rate in @entity1 receiving @entity1499 confirms the classification of @entity2033 - @entity6822 as highly emetogenic chemotherapy (HEC) and suggests that ID- @entity6822 be reclassified as HEC.

Poor chemotherapy-induced @entity1209 control in XXXX receiving intermediate or high dose @entity1499 .

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Patient'] @entity2749 :: ('MESH:C580065', 'Disease') :: ['Emetic episodes'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity3974 :: ('MESH:D017294', 'Chemical') :: ['ondansetron'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity2033 :: ('MESH:D006816', 'Disease') :: ['HD'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity10442 :: ('MESH:D017829', 'Chemical') :: ['granisetron'] @entity4609 :: ('176652', 'Species') :: ['CIV'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity36584 :: ('MESH:C011941', 'Chemical') :: ['nabilone'] @entity1209 :: ('MESH:D020250', 'Disease') :: ['nausea and vomiting']
@entity1 :: (9606,Species) :: ['children']
